S&P 500   2,749.98 (+3.41%)
DOW   23,433.57 (+3.44%)
QQQ   200.57 (+2.12%)
AAPL   266.07 (+2.56%)
FB   174.28 (+3.23%)
MSFT   165.13 (+1.00%)
GOOGL   1,207.00 (+2.07%)
AMZN   2,043.00 (+1.56%)
CGC   14.83 (+2.28%)
NVDA   266.95 (+3.06%)
BABA   195.98 (-1.02%)
MU   48.29 (+3.76%)
GE   7.30 (+3.84%)
TSLA   548.84 (+0.62%)
AMD   48.79 (+2.59%)
T   29.89 (-0.63%)
ACB   0.85 (+6.23%)
F   5.03 (+6.79%)
NFLX   371.12 (-0.31%)
BAC   23.45 (+5.92%)
GILD   74.99 (+0.43%)
DIS   101.07 (-0.17%)
PRI   97.51 (+10.73%)
S&P 500   2,749.98 (+3.41%)
DOW   23,433.57 (+3.44%)
QQQ   200.57 (+2.12%)
AAPL   266.07 (+2.56%)
FB   174.28 (+3.23%)
MSFT   165.13 (+1.00%)
GOOGL   1,207.00 (+2.07%)
AMZN   2,043.00 (+1.56%)
CGC   14.83 (+2.28%)
NVDA   266.95 (+3.06%)
BABA   195.98 (-1.02%)
MU   48.29 (+3.76%)
GE   7.30 (+3.84%)
TSLA   548.84 (+0.62%)
AMD   48.79 (+2.59%)
T   29.89 (-0.63%)
ACB   0.85 (+6.23%)
F   5.03 (+6.79%)
NFLX   371.12 (-0.31%)
BAC   23.45 (+5.92%)
GILD   74.99 (+0.43%)
DIS   101.07 (-0.17%)
PRI   97.51 (+10.73%)
S&P 500   2,749.98 (+3.41%)
DOW   23,433.57 (+3.44%)
QQQ   200.57 (+2.12%)
AAPL   266.07 (+2.56%)
FB   174.28 (+3.23%)
MSFT   165.13 (+1.00%)
GOOGL   1,207.00 (+2.07%)
AMZN   2,043.00 (+1.56%)
CGC   14.83 (+2.28%)
NVDA   266.95 (+3.06%)
BABA   195.98 (-1.02%)
MU   48.29 (+3.76%)
GE   7.30 (+3.84%)
TSLA   548.84 (+0.62%)
AMD   48.79 (+2.59%)
T   29.89 (-0.63%)
ACB   0.85 (+6.23%)
F   5.03 (+6.79%)
NFLX   371.12 (-0.31%)
BAC   23.45 (+5.92%)
GILD   74.99 (+0.43%)
DIS   101.07 (-0.17%)
PRI   97.51 (+10.73%)
S&P 500   2,749.98 (+3.41%)
DOW   23,433.57 (+3.44%)
QQQ   200.57 (+2.12%)
AAPL   266.07 (+2.56%)
FB   174.28 (+3.23%)
MSFT   165.13 (+1.00%)
GOOGL   1,207.00 (+2.07%)
AMZN   2,043.00 (+1.56%)
CGC   14.83 (+2.28%)
NVDA   266.95 (+3.06%)
BABA   195.98 (-1.02%)
MU   48.29 (+3.76%)
GE   7.30 (+3.84%)
TSLA   548.84 (+0.62%)
AMD   48.79 (+2.59%)
T   29.89 (-0.63%)
ACB   0.85 (+6.23%)
F   5.03 (+6.79%)
NFLX   371.12 (-0.31%)
BAC   23.45 (+5.92%)
GILD   74.99 (+0.43%)
DIS   101.07 (-0.17%)
PRI   97.51 (+10.73%)
Log in

NYSE:JNJJohnson & Johnson Stock Price, Forecast & News

$143.26
+5.78 (+4.20 %)
(As of 04/8/2020 04:00 PM ET)
Add
Compare
Today's Range
$137.30
Now: $143.26
$144.13
50-Day Range
$111.14
MA: $135.25
$150.13
52-Week Range
$109.16
Now: $143.26
$154.50
Volume10.75 million shs
Average Volume10.66 million shs
Market Capitalization$377.68 billion
P/E Ratio21.13
Dividend Yield2.76%
Beta0.65
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular diseases; sterilization and disinfection products to reduce surgical infection; diabetes care products; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. It has research and collaboration alliance with Morphic Therapeutic. The company was incorporated in 1887 and is based in New Brunswick, New Jersey.
Read More
Johnson & Johnson logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 5.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.49 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP47816010
Phone732-524-0400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$82.06 billion
Cash Flow$12.30 per share
Book Value$22.60 per share

Profitability

Net Income$15.12 billion

Miscellaneous

Employees132,200
Outstanding Shares2,636,352,000
Market Cap$377.68 billion
Next Earnings Date4/14/2020 (Confirmed)
OptionableOptionable

Receive JNJ News and Ratings via Email

Sign-up to receive the latest news and ratings for JNJ and its competitors with MarketBeat's FREE daily newsletter.


Johnson & Johnson (NYSE:JNJ) Frequently Asked Questions

How has Johnson & Johnson's stock been impacted by COVID-19 (Coronavirus)?

Johnson & Johnson's stock was trading at $131.80 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, JNJ shares have increased by 8.7% and is now trading at $143.26. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Johnson & Johnson?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Johnson & Johnson.

When is Johnson & Johnson's next earnings date?

Johnson & Johnson is scheduled to release its next quarterly earnings announcement on Tuesday, April 14th 2020. View our earnings forecast for Johnson & Johnson.

How can I listen to Johnson & Johnson's earnings call?

Johnson & Johnson will be holding an earnings conference call on Tuesday, April 14th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) released its earnings results on Wednesday, January, 22nd. The company reported $1.88 EPS for the quarter, topping the consensus estimate of $1.87 by $0.01. The company had revenue of $20.75 billion for the quarter, compared to analysts' expectations of $20.83 billion. Johnson & Johnson had a return on equity of 39.27% and a net margin of 22.18%. The business's revenue was up 1.7% on a year-over-year basis. During the same quarter last year, the business posted $1.97 EPS. View Johnson & Johnson's earnings history.

How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?

Johnson & Johnson declared a quarterly dividend on Thursday, January 2nd. Stockholders of record on Tuesday, February 25th will be paid a dividend of $0.95 per share on Tuesday, March 10th. This represents a $3.80 annualized dividend and a yield of 2.65%. The ex-dividend date is Monday, February 24th. View Johnson & Johnson's dividend history.

How will Johnson & Johnson's stock buyback program work?

Johnson & Johnson declared that its Board of Directors has approved a stock repurchase plan on Monday, December 17th 2018, which allows the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to reacquire up to 1.5% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's board of directors believes its shares are undervalued.

What guidance has Johnson & Johnson issued on next quarter's earnings?

Johnson & Johnson updated its FY20 earnings guidance on Wednesday, January, 22nd. The company provided EPS guidance of $8.95-9.10 for the period, compared to the Thomson Reuters consensus EPS estimate of $9.09. The company issued revenue guidance of +4.5-5.5% yr/yr to $85.8-86.2 billion, compared to the consensus revenue estimate of $85.52 billion.

What price target have analysts set for JNJ?

16 equities research analysts have issued 12 month price targets for Johnson & Johnson's stock. Their forecasts range from $140.00 to $173.00. On average, they expect Johnson & Johnson's stock price to reach $157.64 in the next year. This suggests a possible upside of 10.0% from the stock's current price. View analysts' price targets for Johnson & Johnson.

Has Johnson & Johnson been receiving favorable news coverage?

Media headlines about JNJ stock have been trending very negative recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Johnson & Johnson earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutJohnson & Johnson.

Are investors shorting Johnson & Johnson?

Johnson & Johnson saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 20,336,100 shares, an increase of 22.3% from the February 27th total of 16,630,000 shares. Based on an average daily volume of 7,520,000 shares, the days-to-cover ratio is presently 2.7 days. Currently, 0.8% of the company's stock are sold short. View Johnson & Johnson's Current Options Chain.

Who are some of Johnson & Johnson's key competitors?

What other stocks do shareholders of Johnson & Johnson own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Johnson & Johnson investors own include AT&T (T), Walt Disney (DIS), Verizon Communications (VZ), Pfizer (PFE), Cisco Systems (CSCO), Intel (INTC), Procter & Gamble (PG), JPMorgan Chase & Co. (JPM), Exxon Mobil (XOM) and Home Depot (HD).

Who are Johnson & Johnson's key executives?

Johnson & Johnson's management team includes the following people:
  • Mr. Alex Gorsky, Chairman & CEO (Age 59)
  • Mr. Joseph J. Wolk CPA, Exec. VP & CFO (Age 52)
  • Dr. Paulus A. Stoffels, Chief Scientific Officer (Age 57)
  • Mr. Michael H. Ullmann, Exec. VP & Gen. Counsel (Age 60)
  • Mr. Joaquin Duato, Vice Chairman of Exec. Committee (Age 56)

What is Johnson & Johnson's stock symbol?

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

Who are Johnson & Johnson's major shareholders?

Johnson & Johnson's stock is owned by a variety of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.02%), Park National Corp OH (0.01%), Cacti Asset Management LLC (0.01%), Neville Rodie & Shaw Inc. (0.01%), Cullinan Associates Inc. (0.01%) and Cardinal Capital Management Inc. (0.00%). Company insiders that own Johnson & Johnson stock include Alex Gorsky, Charles Prince, Hubert Joly, Joaquin Duato, Kathryn E Wengel, Marillyn A Hewson, Michael E Sneed, Peter Fasolo, Ronald A Kapusta and William D Perez. View institutional ownership trends for Johnson & Johnson.

Which institutional investors are selling Johnson & Johnson stock?

JNJ stock was sold by a variety of institutional investors in the last quarter, including LGT Capital Partners LTD., M&R Capital Management Inc., Park National Corp OH, Chickasaw Capital Management LLC, Xcel Wealth Management LLC, Chemung Canal Trust Co., Cardinal Capital Management Inc., and RDA Financial Network. Company insiders that have sold Johnson & Johnson company stock in the last year include Kathryn E Wengel, and Michael E Sneed. View insider buying and selling activity for Johnson & Johnson.

Which institutional investors are buying Johnson & Johnson stock?

JNJ stock was acquired by a variety of institutional investors in the last quarter, including IBM Retirement Fund, State of Alaska Department of Revenue, Cacti Asset Management LLC, American National Bank, First American Bank, Gradient Investments LLC, Grassi Investment Management, and Lake Street Financial LLC. Company insiders that have bought Johnson & Johnson stock in the last two years include Charles Prince, Hubert Joly, Marillyn A Hewson, and William D Perez. View insider buying and selling activity for Johnson & Johnson.

How do I buy shares of Johnson & Johnson?

Shares of JNJ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Johnson & Johnson's stock price today?

One share of JNJ stock can currently be purchased for approximately $143.26.

How big of a company is Johnson & Johnson?

Johnson & Johnson has a market capitalization of $377.68 billion and generates $82.06 billion in revenue each year. The company earns $15.12 billion in net income (profit) each year or $8.68 on an earnings per share basis. Johnson & Johnson employs 132,200 workers across the globe. View additional information about Johnson & Johnson.

What is Johnson & Johnson's official website?

The official website for Johnson & Johnson is http://www.jnj.com/.

How can I contact Johnson & Johnson?

Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company can be reached via phone at 732-524-0400.

This page was last updated on 4/8/2020 by MarketBeat.com Staff

Featured Article: Investing in Growth Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel